Minorities often distrust breast cancer screening
Distrust of healthcare providers and may contribute to the low levels of compliance for breast cancer screening among minorities.
Distrust of healthcare providers and may contribute to the low levels of compliance for breast cancer screening among minorities.
A study by Michigan State University of 341 women, including African American, Arab American, and Hispanic women, found that more than two-thirds of those subjects believe that healthcare organizations sometimes mislead or even purposely deceive patients. The study was presented at the 2009 American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Carefree, AZ.
Another study, in the Journal of Women’s Health, assessed the attitudes toward screening of 150 lesbian/bisexual and 400 heterosexual women. It revealed negative beliefs about mammography, lower levels of provider trust, and less perceived risk of breast cancer among lesbian/bisexual women (2009;18[2]:177-185).
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
